Discordance in the paraoxonase (Pon1)-192QR polymorphism

Rozaida Poh and Sekaran Muniandy

Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Keywords: PON1 gene, PCR-based genotyping, Two-substrate assay genotyping, Paraoxon, Diazoxon, Sequencing.

Abstract

Paraoxonase (PON1) has been implicated to have a cardioprotective role, due to its physical attachment with high-density lipoprotein. PON1-192QR is a variation of the PON1 gene, the R allele being a risk factor for cardiovascular disease. Kinetic studies resulting in a plot of paraoxon versus diazoxon hydrolysis rates may be used to accurately predict PON1-192 genotype. In this study, paraoxonase and diazoxonase activities in plasma were measured spectrophotometrically using plasma while PCR-based PON1-192 genotyping was performed using polymerase chain reaction followed by restriction digestion. The two-substrate assay-derived genotypes were cross-referred with those determined by PCR-based genotyping. When results did not concur, sequencing of the 99-bp region spanning codon 192 of PON1 was performed to verify the genotype. Concordant samples with high or low activities were sequenced for comparison. In addition, the rare PON1-194WX polymorphism was examined as a source of discordance. The frequency of the PON1-192Q allele in a Malaysian population comprising three ethnic groups (Malays, Chinese and Indians) was estimated to be 0.46, and that of the PON1-192R allele, 0.54. Discordance between the genotype and phenotype was observed for two samples. One of the two subjects genotyped as PON1-192QR and phenotyped as PON1-192QQ showed low paraoxonase and diazoxonase activities. Sequencing confirmed that the genotype was PON1-192QR. The other subject was genotyped as PON1-192RR but phenotyped as PON1-192QR. Sequencing showed that the genotype was in fact PON1-192RR, with the subject showing relative high activities. The PON1-194WX mutation was not detected in the sequenced samples and was not the source for discordance.

Introduction

Paraoxonase1 (PON1) is an esterase belonging to a family of proteins that includes PON2 and PON3 [1]. The genes coding for the PON family are located on human chromosome 7 (q21.22). PON1 has two exonic amino acid polymorphisms, one at position 55 (methionine/leucine; M/L) and another at position 192 (arginine/glutamine; R/Q). PON1 is associated with high-density lipoprotein (HDL) particles, thus linked to the prevention of oxidative damage to low-density lipoprotein (LDL) particles. The protective effect of HDL has been implicated in arresting the development of coronary heart disease (CHD), as well as other vascular complications of diabetes [2]. Several studies describe the PON1-192Q allele as a significant risk factor for heart disease although a meta-analysis of 43 such studies have shown a weak association whereby the estimated relative risk of PON1-192Q for coronary heart disease was 1.12 [3]. Thus genotyping the diabetic individuals for both the PON1-192QR and 55LM polymorphisms updates available data and would be useful in identifying those individuals at the highest risk of developing complications. The characteristics of PON1-192OQ, -QR and -RR genotypes are such that the plasma activity differs towards the substrates paraoxon and diazoxon. The PON1-192Q polymorphism causes a ten-fold decrease in paraoxonase activity. The PON1-192R mutation possibly reshapes the active site thereby improving the positioning of paraoxon [4]. In addition, hydrophobicity is common to most of PON1’s effective substrates, probably due to the hydrophobicity and depth of PON1’s active site. Therefore, the poor and effective substrates bind at the active site with similar affinity, except that the mode of binding differs; the poor substrates would be inadequately positioned, resulting in a lower activity.

Material and Methods

Outpatients who attended the Diabetic Clinic, University of Malaya Medical Centre, Kuala Lumpur, and healthy
Table 1: Characteristics of subjects with discordant PON1192 genotypes in comparison with selected Concordant samples

<table>
<thead>
<tr>
<th>Group</th>
<th>Discordant</th>
<th>Discordant</th>
<th>Low POase activity</th>
<th>Low DZOase activity</th>
<th>High POase activity</th>
<th>High DZOase activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PON1192 genotype</td>
<td>QR</td>
<td>RR</td>
<td>QR</td>
<td>RR</td>
<td>RR</td>
<td>QQ</td>
</tr>
<tr>
<td>PON1192 phenotype</td>
<td>QQ</td>
<td>QR</td>
<td>QR</td>
<td>RR</td>
<td>RR</td>
<td>QQ</td>
</tr>
<tr>
<td>PON1192 genotype (sequenced)</td>
<td>QR</td>
<td>RR</td>
<td>QR</td>
<td>RR</td>
<td>RR</td>
<td>QQ</td>
</tr>
<tr>
<td>POase activity (U/L)</td>
<td>143</td>
<td>599</td>
<td>107</td>
<td>765</td>
<td>1049</td>
<td>315</td>
</tr>
<tr>
<td>DZOase activity (U/L)</td>
<td>10030</td>
<td>14037</td>
<td>3819</td>
<td>6770</td>
<td>4985</td>
<td>27571</td>
</tr>
<tr>
<td>PON155 genotype</td>
<td>LL</td>
<td>LL</td>
<td>LL</td>
<td>LL</td>
<td>LL</td>
<td>LL</td>
</tr>
<tr>
<td>Age (years)</td>
<td>29</td>
<td>43</td>
<td>52</td>
<td>58</td>
<td>53</td>
<td>45</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Malay</td>
<td>Malay</td>
<td>Chinese</td>
<td>Malay</td>
<td>Malay</td>
<td>Malay</td>
</tr>
<tr>
<td>Diabetes/Cardiovascular</td>
<td>None</td>
<td>None</td>
<td>Diabetic/</td>
<td>Hypertensive</td>
<td>Hypertensive</td>
<td>Hypertensive</td>
</tr>
<tr>
<td>complications</td>
<td></td>
<td></td>
<td>complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.16</td>
<td>0.93</td>
<td>0.71</td>
<td>0.82</td>
<td>1.63</td>
<td>1.10</td>
</tr>
</tbody>
</table>

Demographic characteristics of each subject were recorded. All subjects were screened for the variations in the PON1 gene, including unmatched cases or controls. Venous blood samples were obtained by a trained phlebotomist under sterile conditions from subjects. Genomic DNA was extracted from whole EDTA blood using a Gene All Blood DNA Purification kit (General Biosystem, Seoul, South Korea). PON1 genotypes were determined by the PCR-based methods [5]. To assess polymorphism at position 192, the sense primer (5’ TAT TGT TGC TGT GGG ACC TGA G 3’) and the antisense primer (5’ CAC GCT AAA CCC AAA TAC ATC TC 3’) which encompass the codon 192 of the human PON1 gene were used. For the polymorphism at position 55, the sense primer (5’ AGA GGA TTC AGT CTT TGA GGA AA 3’) and the antisense primer (5’ CTG CCA GTC CTA GAA AAC GTT 3’) were used. PCR reactions were carried out using a Hybaid Omnigene thermal cycler (Hybaid, Middlesex, UK). The hot-start PCR reaction mixture for the PON1-192 polymorphism contained 100 ng of DNA template, 0.5 μM of each primer, 1.5 mM MgCl₂, 200 μM of each dNTP and 1 unit of Taq DNA polymerase (Biotherm). After denaturation for 5 min at 94°C, the reaction mixture was subjected to 35 cycles of 30 sec of denaturation at 94°C, 30 sec of annealing at 61°C and 30 sec of extension at 72°C. The final extension time was 7 min at 72°C. The 386 bp PCR product was digested with NalIII (New England Biolabs) in the presence of BSA overnight at 37°C. Digested products were separated in 3% agarose gels. The L genotype (leucine) does not contain an NalIII site, whereas the M genotype (methionine) contains an NalIII site, giving rise to products of 296 and 90 bp [5]. For two-substrate assays, paraoxonase and diazoxonase activities of corresponding heparinised plasma samples were measured spectrophotometrically (Varian Cary 50, Varian Inc. Scientific, Australia). A two-dimensional plot of diazoxon versus paraoxon hydrolysis rates allowed simultaneous PON1-192 genotyping and activity phenotyping of each individual [6]. The genotypes obtained from both methods were compared. Sequencing was performed to validate genotypes in cases of discordance. Subjects with low activities for their PON1192 genotype were chosen for sequencing.
purposes as follows: $PON1_{192QQ}$ subjects with diazoxonase activities under 5000 U/L, and $PON1_{192QR}$ and $R_R$ subjects with paraoxonase activities less than 200 U/L and 400 U/L, respectively. Reference to figure 1 shows that paraoxonase and diazoxonase activities are low for the subjects identified. The 99-bp PCR product was purified by using a kit (MinElute, Qiagen, The Netherlands) and sequenced on an ABI 3730 DNA Analyzer (Applied Biosystem, California, USA). The sequenced products were compared using the nucleotide blast program against a nucleotide sequence database with reference to Genbank Accession #AF539592 [7]. The presence of the $PON1_{194WX}$ genotype was also examined based on the results from sequencing.

Results and Discussion

Examination of demographic characteristics showed that a greater proportion (60%) of the study population consisted of women. Malays constituted 47% of the study population, followed by Indians (33%) and Chinese (20%). The pooled age range was 17-97 years, with the mean age being 52 ± 13.5 years old. The subjects who were diabetic made up 52 % while the remaining 48 % were the non-diabetic controls. The observed frequencies of $L, M, Q$ and $R$ alleles in the pooled population were 0.912, 0.088, 0.459 and 0.541, respectively. Discordance between the genotype and phenotype was observed for two samples, 29- and 43-year-old, both healthy males. The 29-year-old subject was genotyped as $PON1_{192QR}$ and activity phenotyped as $PON1_{192QQ}$. The sample had low paraoxonase and diazoxonase activities (Table 1). DNA sequencing confirmed that the genotype was $PON1_{192QR}$. This subject had PON1 activity (<200 U/L) in the lowest tertile within its genotype group (Fig. 1). This low activity is consistent with the inactive allele hypothesis whereby the $PON1_{192R}$ allele is predicted to be inactive in this heterozygote.

![Figure 1: Determination of the functional genomics of plasma PON1 using the PON1
t192 bivariate phenotype versus genotype plot. The PON1
t192QQ, -QR and -RR
genotypes are shown as closed circles, triangles and diamonds, respectively. The
two discordant subjects are indicated by open circles.](image)

The 43-year-old subject was genotyped as $PON1_{192RR}$ but phenotyped as $PON1_{192QR}$. Sequencing showed that the genotype was $PON1_{192RR}$, with the subject showing relative high activities. For both samples, the presence of the rare $PON1_{194stop}$ polymorphism ($PON1_{WX}$) which coded for the stop codon was assessed. All the selected samples were confirmed to be of the common $PON1_{194WW}$ genotype. This subject showed comparatively high paraoxonase and diazoxonase activities. As the placement of activity on the plot reflects the differential expression of the $PON1_{192Q}$ and $PON1_{192R}$ alleles, $PON1_{192}$ homozygotes is genotype. In this case, the subject not only displayed discrepant genotypes despite being homozygous, it also displayed high activities.

Repeated genotyping and phenotyping were performed to eliminate the possibility of error. In fact, other reports have noted the incidence of error when the salt-stimulation assay was used. Eckerson et al. [8] noted that one of the two individuals misclassified had low paraoxonase activity. The percentage of error was less than 1%. Browne et al. [9] reported a slightly higher error or ana-
lytical imprecision of 1.0-3.0%. These errors were resolved when the genotypes were compared using various techniques. The rare PON1 protein truncation mutation PON1<sub>trp194stop</sub> may result in diminished PON1 activity. This alteration has been associated with the PON1<sub>192R</sub> allele (Jarvik et al., 2003). In the present study, all subjects sequenced for the mutation carried the PON1<sub>194WW</sub> genotype which was not the stop codon, thereby ruling out the effect of the stop codon on the loss of function of the particular allele. This is to be expected as the allele frequency of such a mutation occurring is relatively low at 1/458 PON1<sub>192R</sub> alleles in the population studied by Jarvik et al. (2003).

**Acknowledgements**

This study was supported by both the PPF FP030/2005D and PPP No P0117/2007A grants from the University of Malaya, Malaysia.

**References**


**Correspondence:**

Rozaida Poh
Department of Molecular Medicine
Faculty of Medicine, University of Malaya
50603 Lembah Pantai
Kuala Lumpur
Malaysia.

Phone: +603 79674717
Fax: +603 79674957
e-mail: rozaiday@yahoo.com.